Introduction
============

Congenital hypothyroidism is one of the most preventable causes of neurocognitive impairment because early treatment is possible in neonates \[[@b1-apem-2017-22-4-253],[@b2-apem-2017-22-4-253]\]. The thyroid hormone is important for normal growth and development in infancy \[[@b3-apem-2017-22-4-253],[@b4-apem-2017-22-4-253]\]. After introducing national screening test (NST) using capillary thyroid stimulating hormone (TSH) level, the incidence of untreated congenital hypothyroidism has significantly decreased \[[@b5-apem-2017-22-4-253]\].

According to the Italian Registry of Congenital Hypothyroidism, congenital heart disease (CHD) is the most frequent disease condition associated with congenital hypothyroidism \[[@b6-apem-2017-22-4-253]\]. CHD is also reported to be a risk factor for nonautoimmune hypothyroidism in children \[[@b7-apem-2017-22-4-253]\]. In addition, intravenous iodine contrast media (ICM) is frequently used for diagnostic imaging and therapeutic intervention in CHD patients. Excess iodine exposed by ICM may disturb thyroid function in adult and pediatric population \[[@b8-apem-2017-22-4-253]-[@b11-apem-2017-22-4-253]\]. However, there is no generally accepted guideline for screening thyroid dysfunction in CHD infants.

The 2014 European Society of Pediatric Endocrinology (ESPE) guideline recommends a second screening of thyroid function test (TFT) in neonates with the following high risk factors for hypothyroidism; preterm or low birth weight infants, critically ill infants who were admitted to intensive care unit (ICU), and monozygotic twins \[[@b12-apem-2017-22-4-253]\]. Currently, secondary TFT screening in CHD infants is not different from that in those without CHD. Meanwhile, ICM exposure is not an absolute indication for TFT screening to detect thyroid dysfunction yet.

In this study, we aimed to identify frequency and clinical course of thyroid dysfunction in CHD infants who received TFT screening within 100 days according to current ESPE guidelines. We also aimed to identify the role of ICM exposure on developing thyroid dysfunction in CHD infants.

Materials and methods
=====================

1. Subjects and methods
-----------------------

The medical records of infants diagnosed with CHD between January, 2007 and July, 2016 at Seoul National University Children's Hospital were retrospectively reviewed. Those who had TFT results before 100 days of birth were included in this study. Early preterm infants (gestational age \[GA\]\<34 weeks), late preterm infants (34 weeks≤GA\<37 weeks) with spontaneously closed patent foramen ovale or patent ductus arteriosus, infants whose mother had a history of autoimmune thyroid disease, and patients who expired before 3 years of age were excluded. A total of 54 infants (24 male infants) were finally included in this study.

Clinical data were collected on GA, birth weight, type of cardiac disease, other congenital anomalies, underlying chromosomal or genetic abnormalities, and previous history of medication affecting the thyroid function (dopamine, dobutamine, amiodarone, steroid, and furosemide), exposure to ICM through cardiac computed tomography (CT) or catheterization, operation, and mechanical ventilator care.

Laboratory findings of serum free thyroxine (fT4) and TSH levels from the first to last follow-up were reviewed. Serum concentrations of fT4 and TSH were measured using immunoradiometric kits (RIAKEY; Shin Jin Medics, Seoul, Korea). The normal ranges of serum fT4 and TSH are 0.70--1.80 ng/dL (9.01--23.2 pmol/L) and 0.4--4.1 mIU/L, respectively. A capillary sample of blood was obtained from the heel to preform NST by chemiluminescent Immunoassay (Modular Analysis E 170 module, Roche, Germany). The cutoff values of TSH on NST were \<12 mIU/L. NST results were also reviewed in infants who were transferred from outside hospital.

Patients were categorized into the 3 groups as follows; normal thyroid function, transient thyroid dysfunction, and permanent hypothyroidism. In infants who started levothyroxine medication, the dose, starting and ending dates of levothyroxine medication were reviewed. The transient thyroid dysfunction group included infants who showed transient hyperthyrotropinemia which spontaneously normalized or those who successfully discontinued levothyroxine during follow-up. Patients who failed to discontinue or withdraw levothyroxine medication till 3 years of age were categorized into permanent hypothyroidism.

2. Statistical analysis
-----------------------

Statistical analyses were performed using IBM SPSS Statistics ver. 24.0 (IBM Co., Armonk, NY, USA). Analysis for normality was performed first. All continuous variables were described as means±standard deviation. Binary logistic regression analysis was performed to investigate risk factors associated with transient thyroid dysfunction. A *P*-value of \<0.05 was considered statistically significant.

3. Ethics statement
-------------------

The present study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (approval number: 1702-021-829) and informed consent was waved.

Results
=======

1. Clinical characteristics of total subjects
---------------------------------------------

[Table 1](#t1-apem-2017-22-4-253){ref-type="table"} shows the baseline characteristics of the total 54 infants. The mean age at initial TFT check-up was 32.2±27.7 (range, 3--98) days after birth. Thirty-two patients (59.3%) had NST results available and 6 of these patients had elevated TSH levels on their NST. The mean age at last follow-up was 5.3±2.9 years. Eighteen patients (33.3%) had normal thyroid function. Among 36 patients with thyroid dysfunction, 29 infants (53.7%) had transient thyroid dysfunction, and 7 patients (13.0%) had permanent hypothyroidism ([Fig, 1](#f1-apem-2017-22-4-253){ref-type="fig"}, [Table 1](#t1-apem-2017-22-4-253){ref-type="table"}).

Thirteen patients (24.1%) were late preterm (34 to 36 weeks of GA) and 11 patients (20.4%) were small for GA. The CHDs of the patients were as follows; ventricular septal defect (n=21), atrial septal defect (n=15), atrioventricular septal defect (n=1), tetralogy of Fallot (n=6), pulmonary stenosis (n=5), Ebstein anomaly (n=2), functional single ventricle (n=1), thoracic aorta widening (n=1), mitral regurgitation (n=1), and truncus arteriosus (n=1). Twenty-three patients (42.6%) were diagnosed with chromosomal anomaly or genetic syndrome as follows: Down syndrome (n=11), other chromosomal defects (n=2, 46, XY, del(9)(p22), and 45, XX, -14, der(18), t(14;18)(q11.2;q23)), Digeorge syndrome (n=5), Williams syndrome (n=3), Beckwith-Wiedemann syndrome (n=1), and Alagille syndrome (n=1). Before evaluation of TFTs, 5 infants (9.3%) received cardiac surgery, 8 infants (14.8%) had a history of ICM exposure, and 15 infants (27.8%) had a history of thyroid disrupting medication such as dopamine, dobutamine, amiodarone, steroids, and/or furosemide ([Table 1](#t1-apem-2017-22-4-253){ref-type="table"}).

2. Clinical characteristics of CHD patients with permanent hypothyroidism
-------------------------------------------------------------------------

Among 7 patients categorized into the permanent hypothyroidism group ([Table 2](#t2-apem-2017-22-4-253){ref-type="table"}), 3 patients with Down syndrome (n=2, cases 1 and 2), and Williams syndrome (n=1, case 3) were included. Three of the remaining 4 patients without an underlying genetic syndrome were detected by elevated TSH levels on NST (cases 4--6). However, 1 patient (case 7, [Table 2](#t2-apem-2017-22-4-253){ref-type="table"}) was diagnosed with hypothyroidism 92 days after birth since delayed TSH elevation was detected in the ICU during the evaluation of feeding cyanosis and macroglossia.

3. Factors associated with transient thyroid dysfunction in infants with CHD
----------------------------------------------------------------------------

Among 29 patients categorized into the transient thyroid dysfunction group, 8 patients initially started levothyroxine and successfully discontinued medication at a later follow-up. The remaining 21 patients showed transient hyperthyrotropinemia which was spontaneously normalized without medication ([Fig. 1](#f1-apem-2017-22-4-253){ref-type="fig"}).

The transient thyroid dysfunction group (n=29) had higher proportions of patients with a chromosomal anomaly or genetic syndrome, preterm birth, small for GA, history of ICM exposure, and use of thyroid disrupting medication than the normal thyroid function group (n=18). However, none of aforementioned risk factors including ICM exposure was statistically significant as a result of binary logistic regression analysis ([Supplementary Table 1](#SD1-apem-2017-22-4-253){ref-type="supplementary-material"}).

4. Clinical course of patients who had a history of ICM exposure
----------------------------------------------------------------

A total of 8 patients who had a history of ICM exposure were categorized into permanent hypothyroidism (n=3) or transient thyroid dysfunction (n=5, [Table 3](#t3-apem-2017-22-4-253){ref-type="table"}) group. Three patients with permanent hypothyroidism had already elevated levels of TSH before ICM exposure, suggesting congenital defects regardless of ICM exposure. When we closely looked at the 5 patients with transient thyroid dysfunction, we observed TSH levels increased 3 to 24 days after ICM exposure. Three of these 5 patients started levothyroxine medication and successfully discontinued before 3 years of age (cases 1, 4, and 5; [Table 3](#t3-apem-2017-22-4-253){ref-type="table"}).

Discussion
==========

The prevalence of vitamin D deficiency in pediatric patients Two-thirds of the 54 CHD infants who received TFT screening within 100 days according 2014 ESPE guideline showed thyroid dysfunction. Seven patients (13%) were categorized into permanent hypothyroidism requiring persistent levothyroxine medication. Twenty-one infants (53.7%) with transient thyroid dysfunction had lower birth weight, and had more exposure to ICM and/or thyroid disrupting medication than those with normal thyroid function; however, none of risk factors including ICM exposure were statistically significant in this study. Despite normal NST results, delayed TSH elevation was detected in critically ill patient with CHD during ICU care. Unless CHD infants had elevated TSH levels before ICM exposure, thyroid dysfunction was transient in this study.

Seven patients with permanent hypothyroidism received TFTs according to the 2014 ESPE guideline \[[@b12-apem-2017-22-4-253]\], since they had risk factors for thyroid dysfunction such as Down syndrome, Williams syndrome, low birth weight, and/or ICU admission. Despite normal results of NST, TFT needs to be evaluated if CHD infants had risk factors for thyroid dysfunction. This study supports the current guideline recommending second TFT screening in CHD infants who had known risk factors related to thyroid dysfunction.

Half of CHD infants (53.7%) with risk factors showed transient thyroid dysfunction. Preterm birth and/or low birth weight \[[@b13-apem-2017-22-4-253]-[@b15-apem-2017-22-4-253]\], thyroid disrupting medication \[[@b16-apem-2017-22-4-253]-[@b18-apem-2017-22-4-253]\], and exposure to disinfectant containing iodine and/or ICM \[[@b8-apem-2017-22-4-253]-[@b11-apem-2017-22-4-253],[@b19-apem-2017-22-4-253]-[@b22-apem-2017-22-4-253]\] were included as candidate risk factors for developing transient thyroid dysfunction in this study. Intrauterine stress with growth restriction and compensatory response to mild suppression of the thyroid gland \[[@b23-apem-2017-22-4-253]\], a significant reduction of the expression of thyroid receptor isoforms in the fetal brain with intrauterine growth restriction and the resetting of TSH sensitivity \[[@b24-apem-2017-22-4-253]\] may affect thyroid function. Having a history of dopamine, dobutamine, furosemide, steroid \[[@b16-apem-2017-22-4-253],[@b17-apem-2017-22-4-253]\] and amiodarone18) was known to affect thyroid function. Meanwhile, diagnostic tools using ICM such as cardiac CT, and catheterization are being increasingly performed, especially for evaluation of cardiac structural anomaly. Thyroid dysfunction after ICM exposure has been reported in adults \[[@b11-apem-2017-22-4-253],[@b20-apem-2017-22-4-253]\] and infants with CHD \[[@b21-apem-2017-22-4-253],[@b22-apem-2017-22-4-253]\]. However, none of candidate risk factors was statistically significant in our study.

Recently, three term CHD infant cases were reported, who developed iodine-induced hypothyroidism 5 to 11 days after exposure to ICM and/or disinfectant containing iodine \[[@b19-apem-2017-22-4-253]\], which emphasizes that the thyroid function needs to be evaluated after excess iodine exposure in CHD infants. Two of these 3 infants had transient hypothyroidism, and one had severe hypothyroidism requiring ongoing thyroid replacement in the aforementioned study \[[@b19-apem-2017-22-4-253]\]. Iodine induced hypothyroidism is explained by failure to escape the Wolff-Chaikoff effect \[[@b10-apem-2017-22-4-253]\]. In healthy individuals, despite iodine excess, thyroid hormone homeostasis is maintained by the acute Wolff-Chaikoff effect by transient inhibition of thyroid hormone synthesis through decreased organification. Typically, the thyroid escapes from the acute Wolff-Chaikoff effect within a few days through down regulation of the sodium-iodine symporter in thyroid cells, and then normal thyroid hormone synthesis resumes \[[@b10-apem-2017-22-4-253]\]. However, in CHD infants, the thyroid cannot escape the Wolff-Chaikoff effect, resulting in thyroid dysfunction \[[@b19-apem-2017-22-4-253]\]. Although all CHD infants who had a history of ICM showed thyroid dysfunction at 3 to 24 days after exposure in our study, the independent pathogenic role of ICM exposure on thyroid dysfunction was not found. Except 3 patients who already had elevated TSH levels before ICM exposure, 5 patients successfully recovered from transient thyroid dysfunction.

This study is limited by a retrospective design and small sample size. Since infants at high risk for developing thyroid dysfunction selectively received TFTs in our study, we could not know the incidence of congenital hypothyroidism for the total CHD infants due to selection bias. Since the possibility of common mechanisms such as the pathologic role of *NKX2.5* or *TBX1* coding sequences on the thyroid and heart development has been suggested \[[@b25-apem-2017-22-4-253],[@b26-apem-2017-22-4-253]\], further study is needed to discover whether CHD itself is independently associated with congenital hypothyroidism.

In conclusion, thyroid dysfunction was detected in two-third of CHD infants who received TFT screening within 100 days according to current ESPE guidelines (53.7% transient, 13.0% permanent), although NST results were normal. The independent effect of ICM exposure on thyroid dysfunction was not identified in this study. Further studies with larger sample sizes are required to revise criteria for TFT screening in CHD infants.
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###### 

Characteristics of total subjects

  Characteristic                            Total       Normal      Transient thyroid dysfunction   Permanent hypothyroidism
  ----------------------------------------- ----------- ----------- ------------------------------- --------------------------
  No. of patients                           54          18 (33.3)   29 (53.7)                       7 (13.0)
  Male sex                                  24 (44.4)   6 (33.3)    14 (48.3)                       4 (57.1)
  Gestational age (wk)                      37.8±1.7    38.2±1.7    37.6±1.8                        37.7±1.0
  Birth weight (kg)                         2.9±0.7     3.1±0.6     2.9±0.7                         2.5±0.5
  Preterm                                   13 (24.1)   3 (16.7)    9 (31.0)                        1 (14.3)
  Small for gestational age                 11 (20.4)   2 (11.1)    7 (24.1)                        2 (28.6)
  Chromosomal anomaly or genetic syndrome   23 (42.6)   6 (33.3)    14 (48.3)                       3 (42.9)
  Cyanotic heart disease                    17 (31.5)   6 (33.3)    8 (27.6)                        3 (42.9)
  Ventilator care history                   8 (14.8)    3 (16.7)    5 (17.2)                        1 (14.3)
  History of surgery                        5 (9.3)     1 (5.6)     3 (10.3)                        1 (14.3)
  Exposure to iodine contrast media         8 (14.8)    0 (0)       5 (17.2)                        3 (42.9)
  Thyroid disrupting medication             15 (27.8)   2 (11.1)    10 (34.5)                       3 (42.9)

Values are presented as number (%) or mean±standard deviation.

###### 

Congenital heart disease infants with permanent hypothyroidism

  Case   Sex   Congenital heart disease      Underlying disease   GA (wk)   Birth weight (kg)   TSH (NST) (mIU/L)      Age at detection of elevated TSH (day)   Serum fT4 (ng/dL)   Serum TSH (mIU/L)   Age at start levothyroxine (day)   Imaging study     Age at last follow-up (yr)
  ------ ----- ----------------------------- -------------------- --------- ------------------- ---------------------- ---------------------------------------- ------------------- ------------------- ---------------------------------- ----------------- ----------------------------
  1      M     TOF                           Down syndrome        39        2.3                 Normal (2.9)           26                                       1.7                 8.9                 628                                NA                8.0
  2      F     AVSD, PDA                     Down syndrome        36        1.8                 Normal (6.8)           7                                        1.9                 8.2                 21                                 NA                3.9
  3      M     AS, PS                        Williams syndrome    38        2.6                 NA                     83                                       1.0                 5.5                 130                                NA                9.2
  4      F     Large VSD, ASD, PDA           None                 38        2.2                 Elevated (44.8)        17                                       0.65                100                 18                                 NA                8.3
  5      M     Functional single ventricle   None                 38        3.2                 Elevated (14.5)        7                                        1.18                28.0                380                                NA                3.7
  6      F     IAA, PDA,VSD                  None                 37        2.6                 Elevated (157)         17                                       0.10                801.0               17                                 Lingual thyroid   6.1
  7      M     Large ASD                     None                 38        3.0                 Normal (NA, outside)   92                                       0.89                22.3                92                                 NA                6.5

Normal values of TSH (NST), serum fT4, and serum TSH were ≤12 mIU/L, 0.70--1.80 ng/dL, and 0.4--4.1 mIU/L, respectively.

GA, gestational age; TSH, thyroid stimulating hormone; NST, neonatal screening test; fT4, free thyroxine; TOF, tetralogy of Fallot; AVSD, atrioventricular septal defect; PDA, patent ductus arteriosus; AS, aortic stenosis; PS, pulmonary stenosis; VSD, ventricular septal defect; ASD, atrial septal defect; IAA, interrupted aortic arch; NA, not available.

###### 

Congenital heart disease infants with transient thyroid dysfunction after exposure to iodine contrast media (ICM)

  Case   Sex   Congenital heart disease   Underlying disease   Birth weight (kg)   TSH (NST) (mIU/L)   Serum TSH before exposure to ICM   Exposure to ICM (age \[day\] at exposure)   Serum TSH after exposure to ICM (age \[day\] at evaluation)   Levothyroxine medication (dose, age \[day\] at start)   Levothyroxine withdrawal (age \[day\] atdiscontinuation)   Imaging study
  ------ ----- -------------------------- -------------------- ------------------- ------------------- ---------------------------------- ------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- ---------------
  1      F     IAA, VSD, ASD              Digeorge syndrome    2.5                 Normal (9.5)        4.0                                CT angiography (13)                         23.04 (25)                                                    Yes (15.5 µg/kg/day at 25)                              Yes (33)                                                   NA
  2      F     TOF                        Digeorge syndrome    2.9                 Normal (7.6)        NA                                 CT angiography (4)                          5.4 (20)                                                      No                                                      \-                                                         NA
  3      M     VSD, MR, ASD               46,XY,del(9) (p22)   3.7                 NA                  NA                                 CT angiography (71)                         5.3 (74)                                                      No                                                      \-                                                         NA
  4      F     AP window, ASD, VSD        None                 1.7                 Normal (1.7)        NA                                 CT angiography (6)                          13.7 (30)                                                     Yes (6.6 µg/kg/day, 30)                                 Yes (889)                                                  Normal
  5      M     VSD, MAPCA                 None                 2.3                 NA                  2.8                                Cardiac catheterization (417)               22.6 (449)                                                    Yes (3.8 µg/kg/day at 449)                              Yes (894)                                                  Normal

Normal values of TSH (NST), and serum TSH were ≤12 mIU/L, and 0.4-4.1 mIU/L, respectively.

TSH, thyroid stimulating hormone; NST, neonatal screening test; IAA, interrupted aortic arch; VSD, ventricular septal defect; ASD, atrial septal defect; CT, computed tomography; TOF, tetralogy of Fallot; MR, mitral regurgitation; AP window, aortopulmonary windrow; MAPCA, major aortopulmonary collateral arteries; NA, not available.
